Angiogenesis in 90Y-Radioembolization of Colorectal Liver Metastases

Alsultan, Ahmed A.; Barentsz, Maarten W.; Smits, Maarten L. J.; Koopman, Miriam; Lam, Marnix G. E. H.; Rosenbaum, C.

doi:10.1053/j.semnuclmed.2019.01.004

Cited by 5 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiangiogenic drugs have been developed for cancer treatment because the activation of the angiogenic process responds to hypoxia. Several studies have focused on angiogenic factors after transarterial treatments of liver tumors ( 9 , 14 , 15 , 16 , 17 , 18 , 19 ). However, most of them have been designed to evaluate the angiogenic response after TACE for HCC ( 16 , 17 , 18 , 19 ).…”

Section: Discussionmentioning

confidence: 99%

“…To date, only three studies have focused on angiogenic markers after TARE ( 9 , 12 , 13 , 14 ), and one included only hepatocellular cancer (HCC) patients ( 12 ). Considering the limited data on this topic, in our pilot study, we included patients with CRCLM and measured circulating angiogenic factors and baseline levels at different time points after TARE.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

Soydal

Araz

Durmaz

et al. 2022

Mirt

View full text Add to dashboard Cite

Objectives: To analyze the change in circulating angiogenic factor levels after transarterial radioembolization (TARE) for colorectal cancer liver metastases (CRCLMs) and its prognostic significance Methods: Blood samples immediately before TARE and on 1 day, 1 week and 6 weeks after were collected for angiogenic factor analysis in 23 patients. Results: Patients with elevated serum basic fibroblast growth factor and platelet-derived growth factor levels in the 1 st week and vascular endothelial growth factor (VEGF) levels in the 6 th week after TARE had significantly shorter median overall survival (OS) times. Conclusion: Some early increases in serum angiogenic factor levels and in serum VEGF in the 6 th week after TARE for CRCLMs are related to short OS and progression-free survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

Soydal

Araz

Durmaz

et al. 2022

Mirt

View full text Add to dashboard Cite

show abstract

“…This accomplishment makes us question whether similar results can be obtained by employing PSMA-RLT in other types of cancer expressing PSMA on tumour cells or the tumour-associated neovasculature. Angiogenesis is defined as a biological process in which new blood vessels are formed from pre-existing ones, leading to the development of the tumour’s blood supply, and it is considered to be a rate-limiting factor in cancer progression [ 24 , 25 ]. These findings were the basis for the development and the introduction into clinical practice of antineoangiogenic treatments [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?

Rizzo

Dall’Armellina

Pizzuto

et al. 2022

Cancers

View full text Add to dashboard Cite

Due to its overexpression on the surface of prostate cancer cells, prostate-specific membrane antigen (PSMA) is a relatively novel effective target for molecular imaging and radioligand therapy (RLT) in prostate cancer. Recent studies reported that PSMA is expressed in the neovasculature of various types of cancer and regulates tumour cell invasion as well as tumour angiogenesis. Several authors explored the role of diagnostic and therapeutic PSMA radioligands in various malignancies. In this narrative review, we describe the current status of the literature on PSMA radioligands’ application in solid tumours other than prostate cancer to explore their potential role as diagnostic or therapeutic agents, with particular regard to the relevance of PSMA radioligand uptake as neoangiogenetic biomarker. Hence, a comprehensive review of the literature was performed to find relevant articles on the applications of PSMA radioligands in non-prostate solid tumours. Data on the general, methodological and clinical aspects of all included studies were collected. Forty full-text papers were selected for final review, 8 of which explored PSMA radioligand PET/CT performances in gliomas, 3 in salivary gland malignancies, 6 in thyroid cancer, 2 in breast cancer, 16 in renal cell carcinoma and 5 in hepatocellular carcinoma. In the included studies, PSMA radioligand PET showed promising performance in patients with non-prostate solid tumours. Further studies are needed to better define its potential role in oncological patients management, especially in those undergoing antineoangiogenic therapies, and to assess the efficacy of PSMA-RLT in this clinical context.

show abstract

Radionuclide Therapies and Correlative Imaging

Parihar¹,

Mittra²

2023

Radiology‐Nuclear Medicine Diagnostic Imaging

View full text Add to dashboard Cite

Angiogenesis in 90Y-Radioembolization of Colorectal Liver Metastases

Cited by 5 publications

References 56 publications

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?

Radionuclide Therapies and Correlative Imaging

Contact Info

Product

Resources

About